Disease Landscape and Forecast Insights

The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint…

Clarivate Epidemiology’s coverage of neuronal ceroid lipofuscinosis (NCL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…

Hemophilia A patients are a heterogeneous cohort. The tendency to bleed is highly individual, resulting in a complex management landscape. Two core therapeutic approaches are employed: (1)…

The current treatment armamentarium for non-small-cell lung cancer (NSCLC) is dominated by biomarker-driven therapies and immune checkpoint inhibitors. Therapeutic options in this indication have…

Clarivate Epidemiology’s coverage of Gaucher disease (GD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…